UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

Site Image

Study Overview

Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).
 



Study Description

The main purpose of this study is to test the safety of an oral drug, ibrutinib, added to the standard lymphoma treatment.
 We will also study whether ibrutinib has a helpful effect against HIV and other viruses in our bodies that can cause lymphoma.

Additional Information:

If you meet all of the criteria for being in the study, you will be registered to participate. Trial participation includes one-5 day inpatient stay each treatment cycle. Each treatment cycle is 21 days.

  • Study Identifier: 828995

Recruitment Status

Open

Contact the research team to learn more about this study.

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a study or if you have any questions, please email: psom-ocr@pobox.upenn.edu